<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20160427027633N9</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-08-05</date_registration>
      <primary_sponsor>Kermanshah University of Medical Sciences</primary_sponsor>
      <public_title>Investigating the effect of quince seed mucilage on perineal pain and healing following episiotomy</public_title>
      <acronym></acronym>
      <scientific_title>Investigating the effect of quince seed mucilage on perineal pain and healing following episiotomy: a randomized, double-blind, placebo-controlled study</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-08-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>90</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/71540</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: The mothers will be randomly assigned in to 2groups in order to Block random allocation method with block size of 4, and ratio of 1:1. It works by randomizing participants within blocks such that an equal number are assigned to each treatment. This will be done with Epi Info™6.0 software, Blinding description: The quince seed mucilage and placebo are coded in the same shape and size in two tubes so that only the pharmacist will be aware of the tube content. The researcher, clinical evaluator and statisticians will not be aware of this coding.</study_design>
      <phase>N/A</phase>
      <hc_freetext>episiotomy.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: quince seed mucilage . After mucilage preparation by the pharmacist, researcher and research assistant attends Motazedi Hospital maternity ward. Inclusion criteria will be entered into the study after obtaining written consent. Primiparous women undergoing mediolateral episiotomy will be selected and randomly divided in to two groups: placebo and mucilage and will be coded. Perinatal hygiene training will then be given to all two groups and they will be asked to apply the drug three times daily after rinsing with water and continue for up to 14 days. During this time, the researcher calls to participants by telephone and will be excluded if the drug is not used properly or if complications occur. Then the perineum healing and pain will be examined in the first, seventh, and fourteenth days of peurperium at Razi Hospital in Ahvaz. The VAS and REEDA criteria will be evaluated. Intervention 2: Control group: Placebo. The action is according to the intervention group. The gel formulation used in the placebo group (placebo gel) has all the characteristics of the medicinal gel of quince seed mucilage in terms of the components of the formulation (minus the active ingredient of quince seed mucilage). It contains different proportions of carbomer 934P, ethylene glycol and ethanol. After the preparation of the placebo by the pharmacist, the researcher and the research assistant attended the maternity ward of Motazadi Hospital and asked the eligible women to apply it three times a day after washing the perineum with lukewarm water and continue this for 14 days.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no further information. We will decide after the end of the study.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Foruzan Sharifipour</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Isar Square, Daulat Abad Blvd</address>
        <city>Kermanshah</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6719816593</zip>
        <telephone>009838162538</telephone>
        <email>sharifipour_fr91@yahoo.com</email>
        <affiliation>Kermanshah University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Foruzan Sharifipour</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Isar Square, Daulat Abad Blvd</address>
        <city>Kermanshah</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6719816593</zip>
        <telephone>+98 83 3816 2538</telephone>
        <email>sahrifipour@yahoo.com</email>
        <affiliation>Kermanshah University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>First pregnancy
Vertex presentation
Single and term pregnancy
The normal body mass index of the mother is between 19.5 and 24.9
Uncomplicated delivery
Mediolateral episiotomy
Willingness to cooperate</inclusion_criteria>
      <agemin>no limit</agemin>
      <agemax>no limit</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Dystocia
Use of instrumental delivery
Third and fourth degree perineal tears
Any disease in mother and newborn
Withdrawal of participants during the study
Sever postpartum hemorrhage
Any lesion or skin infection in the perineum
Occurrence of any side effects during the intervention
Use of other herbal or medical creams to heal the episiotomy during the intervention</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>O90.1</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Disruption of perineal obstetric wound</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: quince seed mucilage . After mucilage preparation by the pharmacist, researcher and research assistant attends Motazedi Hospital maternity ward. Inclusion criteria will be entered into the study after obtaining written consent. Primiparous women undergoing mediolateral episiotomy will be selected and randomly divided in to two groups: placebo and mucilage and will be coded. Perinatal hygiene training will then be given to all two groups and they will be asked to apply the drug three times daily after rinsing with water and continue for up to 14 days. During this time, the researcher calls to participants by telephone and will be excluded if the drug is not used properly or if complications occur. Then the perineum healing and pain will be examined in the first, seventh, and fourteenth days of peurperium at Razi Hospital in Ahvaz. The VAS and REEDA criteria will be evaluated.</i_keyword>
      <i_keyword>Control group: Placebo. The action is according to the intervention group. The gel formulation used in the placebo group (placebo gel) has all the characteristics of the medicinal gel of quince seed mucilage in terms of the components of the formulation (minus the active ingredient of quince seed mucilage). It contains different proportions of carbomer 934P, ethylene glycol and ethanol. After the preparation of the placebo by the pharmacist, the researcher and the research assistant attended the maternity ward of Motazadi Hospital and asked the eligible women to apply it three times a day after washing the perineum with lukewarm water and continue this for 14 days.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Perineal pain. Timepoint: 1, 7 and 14 days after delivery. Method of measurement: VAS pain visual analog scale.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Episiotomy site healing. Timepoint: 1, 7 and 14 days after delivery. Method of measurement: Rida scale.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Kermanshah University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-07-04</approval_date>
        <contact_name>Ethics committee of Kermanshah University of Medical Sciences</contact_name>
        <contact_address>Shahid Beheshti Blvd., Central Building of Kermanshah University of Medical Sciences Kermanshah Kermanshah Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
